OakChart

Damora Therapeutics Inc

DMRAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:58 AM ET

24.72+0.57 (2.36%)
2026-11-11 16:58 CET
Market cap
1,495.44 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-291.68 USD m
Free cash flow, TTM
-59.13 USD m
EPS diluted, TTM
-122.94
P/E
-
Compare

Price

DMRA against its 20, 50 and 200-day averages
2050200beatmiss
20.0025.0030.0035.004.3M8.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DMRAclose 24.7220-day 21.7550-day 22.47200-day 25.5324.72

35.5% under the 52-week high of 38.33 on 26 Dec 2025. 52-week low 15.00 on 11 Nov 2025. Last 15 sessions, 23.9% high to low

Profile

DMRA
52-week range, 42% of the way up
15.0038.33

Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Waltham, MA.

IndexRUT
Employees7
IPOOct 29, 2020
Beta1.49
ATR, 14d1.73
Rel volume0.27
Short float9.72%
Insider own22.08%
Inst own88.51%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.53B
Enterprise Value1.13B
Income-291.68M
Sales0.00M
Book/sh5.91
Cash/sh8.54
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees7
IPOOct 29, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.19
P/C2.90
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio14.76
Current Ratio14.76
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-122.94
EPS next Y-2.15
EPS next Q-0.55
EPS this Y49.75%
EPS next Y-7.41%
EPS next 5Y13.44%
EPS past 3/5Y-36.14% -34.72%
Sales past 3/5Y- -
EPS Y/Y TTM-916.03%
Sales Y/Y TTM-
EPS Q/Q78.08%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.17.10% -

Ownership

Insider Own22.08%
Insider Trans0.09%
Inst Own88.51%
Inst Trans12.10%
ROA-107.36%
ROE-116.11%
ROIC-58.72%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2013.68%
SMA5010.00%
SMA200-3.16%
Trades-

Technical

Shs Outstand61.90M
Shs Float48.25M
Short Float9.72%
Short Ratio8.69
Short Interest4.69M
52W High38.33 -35.50%
52W Low15.00 64.80%
Volatility11.44% 8.16%
ATR (14)1.73
RSI (14)64.47
Beta1.49
Rel Volume0.27
Avg Volume539.36K
Volume38,739

Performance

Perf Week7.76%
Perf Month33.19%
Perf Quarter-19.56%
Perf Half Y2.32%
Perf YTD7.43%
Perf Year4.83%
Perf 3Y70.48%
Perf 5Y-72.15%
Perf 10Y-
Recom1.00
Target Price46.78
Prev Close24.15
Price24.72
Change %2.36%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Jul 27, 2026InitiatedJJefferiesBuy$50+102.3%
Jun 11, 2026InitiatedHH.C. WainwrightBuy$45+82.0%
Jun 08, 2026InitiatedTTD CowenBuy
May 28, 2026InitiatedWWedbushOutperform$35+41.6%
Apr 24, 2026InitiatedRRBC Capital MktsOutperform$40+61.8%
Mar 25, 2026InitiatedEEvercore ISIOutperform$46+86.1%
Feb 17, 2026InitiatedUUBSBuy$45+82.0%
Jan 07, 2026InitiatedLLeerink PartnersOutperform$46+86.1%
Dec 01, 2025InitiatedGGuggenheimBuy$32+29.4%
Apr 26, 2021ResumedCCredit SuisseOutperform$12-51.5%

Peers

Mkt cap
TickerCompanyMkt cap
GERNGeron Corp641.47M
SNDXSyndax Pharmaceuticals Inc866.05M
KURAKura Oncology Inc706.35M
AGIOAgios Pharmaceuticals Inc1.93B
IRONDisc Medicine Inc3.87B
SLSSELLAS Life Sciences Group Inc1.71B
COAGHemab Therapeutics Holdings Inc1.77B
KROSKeros Therapeutics Inc182.90M
BLSMBlossomHill Therapeutics Inc488.54M
PRLDPrelude Therapeutics Inc316.42M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Jarrett JenniferDirector, President and CEOSep 25 '26Buy20.2312,500252,875512,500Sep 28 07:00 AM
Firmani LoriOfficerAug 05 '26Proposed Sale31.101,80055,980Aug 06 11:34 AM
Winslow GarrettGeneral CounselJul 06 '26Sale29.982457,3452,289Jul 07 08:00 PM
Firmani LoriOfficerJun 22 '26Proposed Sale25.367,615193,140Jun 22 02:27 PM
Bruno JulianneDirectorFeb 09 '26Option Exercise0.00129,0000137,032Feb 12 06:05 AM
Fairmount Funds Management LLCDirectorFeb 09 '26Option Exercise0.008,713,00005,809,000Feb 12 06:03 AM
Schambye Hans T.Chief Executive OfficerJan 02 '26Sale21.3870014,9664,682Jan 06 04:30 PM
Winslow GarrettGeneral CounselJan 02 '26Sale21.382555,4521,854Jan 06 04:30 PM
Firmani LoriChief Financial OfficerJan 02 '26Sale21.411352,890931Jan 06 04:30 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B

News

latest 14 of 206
  • Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.42%
  • Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
  • Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting (GlobeNewswire)
  • Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Loading…
  • Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
  • Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis (GlobeNewswire)
  • Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.11%
  • Damora Announces Redomestication from Delaware to Cayman Islands (GlobeNewswire)
  • Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.67%
  • Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.21%
  • Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.400-0.483-0.4000.000.008
2026Q22026-08-10-0.414-0.414-0.5100.000.008
2026Q12026-05-12-0.620-0.388-0.8090.000.004
2025Q42026-03-19-3.2430.902-121.10.000.003
2025Q32025-11-06-2.360--2.3610.00--
2025Q22025-08-05-2.600--2.5990.00--
2025Q12025-05-08-1.920--1.9160.00--
2024Q32024-11-01-3.390-3.700-3.3910.000.001
2024Q22024-07-31-4.920-6.035-4.9220.000.001
2024Q12024-04-26-126.25-256.25-5.0500.00-1
2023Q42024-03-25-8.750-8.750-5.971-0.001
2023Q32023-12-15-7.500-8.500-7.5040.000.002
2023Q22023-07-31-10.250-14.668-10.1840.000.003
2023Q12023-04-28-12.750-15.625-12.6540.000.002
2022Q42023-03-09-13.750-14.250-13.7190.000.001
2022Q32022-11-08-13.500-17.000-13.4650.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-190.49-163-34.4760.000.00
2021FY-51.250-53.220-51.2160.000.00
2022FY-60.750-61.250-60.6320.000.00
2023FY-36.080-39.000-36.0810.000.00
2024FY-18.530-15.910-18.5270.000.00
2025FY-3.980-1.936-3.9800.000.00
2026FY--2.000--0.00
2027FY--2.148--0.00
2028FY--2.581--0.00
2029FY--2.549--0.00
2030FY--2.586--49.63

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-055000.000.000.00
2026Q4S2026-11-045000.000.000.00
2026Q4S2026-08-115000.000.000.00
2026Q4S2026-06-105000.000.000.00
2026Q4S2026-06-054000.000.000.00
2026Q4S2026-05-273000.000.000.00
2026Q4S2026-05-132000.000.000.00
2026Q4S2026-03-202000.000.000.00
2026Q4S2026-02-062000.000.000.00
2026Q4S2025-11-281000.000.000.00
2026Q4R2026-11-05413-0.61-0.83-0.46
2026Q4R2026-11-04400-0.52-0.60-0.38
2026Q4R2026-10-25400-0.52-0.60-0.38
2026Q4R2026-10-21412-0.52-0.60-0.38

Estimate history

EPS, annual-18.68-41.347-34.476-51.216-60.632-36.081-18.527-152.99-122.9392
Period20182019202020212022202320242025TTM
EPS, quarterly-3.391-5.224-1.916-2.599-2.361-121.103-0.809-0.51-0.517
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.0171.0171.011.011.0261.0851.3171.65861.923
Period20182019202020212022202320242025MRQ
Shares, quarterly1.2541.3171.3221.3251.3271.65860.32161.75361.923
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.350.030.180.830.490.440.190.110.00
Gross Profit-0.35-0.03-0.18-0.83-0.49-0.44-0.19-0.110.00
Selling, General and Administrative Excl. Other129.7036.5316.7235.6360.7251.7933.4538.8612.91
Research and Development98.1126.886.4023.7748.2138.4924.6336.5310.09
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-130.05-36.56-16.90-36.46-61.21-52.23-33.64-38.97-12.91
Interest Expense---0.000.000.000.000.002.97
Unusual Expense174.31174.315.363.450.000.000.000.000.00
Net Income Before Taxes-291.34-209.79-21.40-38.35-61.62-51.75-34.84-36.51-15.87
Income Taxes0.340.050.040.000.000.000.000.000.00
Consolidated Net Income-291.68-209.84-21.44-38.35-61.62-51.75-34.84-36.51-15.87
Net Income From Continuing Operations-291.68-209.84-21.44-38.35-61.62-51.75-34.84-36.51-15.87
Net Income-291.68-209.84-21.44-38.35-61.62-51.75-34.84-42.07-19.00
EPS (Recurring)-2.74-64.03-15.28-33.81-60.63-51.22-34.48-41.35-18.68
EPS (Basic, Before Extraordinaries)-122.94-152.99-18.53-36.08-60.63-51.22-34.48-41.35-18.68
EPS (Diluted)-122.94-152.99-18.53-36.08-60.63-51.22-34.48-41.35-18.68
EBITDA-129.70-36.53-16.72-35.63-60.72-51.79-33.45-38.86-12.91
Non-Operating Income (Expense)13.021.080.861.56-0.420.47-1.202.460.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense23.040.792.565.435.574.481.00-0.08
Shares Outstanding61.921.661.321.081.031.011.011.021.02
Market Capitalization1,495.441,495.446.1219.5229.4276.54316.03334.71-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.260.010.070.010.010.010.010.01
Gross Profit-0.26-0.01-0.07-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other36.6034.9830.7427.383.153.412.592.70
Research and Development25.4825.5423.7823.321.421.470.681.01
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-36.86-34.99-30.81-27.39-3.16-3.42-2.60-2.71
Interest Expense0.00-------
Unusual Expense0.000.000.00174.310.000.000.004.39
Net Income Before Taxes-31.99-30.92-27.74-200.69-3.13-3.43-2.53-6.75
Income Taxes0.000.260.040.040.000.000.00-0.01
Consolidated Net Income-31.99-31.17-27.78-200.74-3.13-3.44-2.53-6.74
Net Income From Continuing Operations-31.99-31.17-27.78-200.74-3.13-3.44-2.53-6.74
Net Income-31.99-31.17-27.78-200.74-3.13-3.44-2.53-6.74
EPS (Recurring)-0.52-0.51-0.81-47.49-2.36-2.60-1.92-2.84
EPS (Basic, Before Extraordinaries)-0.52-0.51-0.81-121.10-2.36-2.60-1.92-5.22
EPS (Diluted)-0.52-0.51-0.81-121.10-2.36-2.60-1.92-5.22
EBITDA-36.60-34.98-30.74-27.38-3.15-3.41-2.59-2.70
Non-Operating Income (Expense)4.874.083.071.000.02-0.010.070.35
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.808.446.410.380.160.140.140.24
Shares Outstanding61.9261.7560.321.661.331.321.321.32
Market Capitalization1,495.441,601.471,561.8536.704.934.514.106.12

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments257.6214.1833.1560.22100.19163.5811.2930.99
Short Term Receivables0.900.881.721.382.282.2141.130.99
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets1.901.781.912.317.633.503.662.98
Total Current Assets260.4216.8436.7763.91110.10169.2956.0834.96
Net Property, Plant & Equipment0.100.130.331.171.040.890.300.00
Total Investments and Advances0.000.000.005.839.050.250.230.14
Intangible Assets0.00-----0.000.00
Other Assets0.000.161.132.282.031.160.000.00
Total Assets260.5317.1338.2373.19122.22171.6056.6135.10
Short Term Debt Incl. Current Port. of LT Debt0.010.010.180.480.400.370.090.00
Accounts Payable0.440.381.703.351.532.853.331.41
Other Current Liabilities19.610.813.947.282.612.344.513.03
Total Current Liabilities20.071.205.8311.114.545.577.934.44
Long Term Debt1.391.420.070.330.450.540.210.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.030.040.000.000.000.000.000.00
Total Liabilities21.492.665.9011.444.996.118.144.44
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value414.910.000.000.000.000.00119.6264.50
Common Equity-175.8714.4732.3361.75117.22165.49-71.15-33.84
Total Shareholders Equity239.0414.4732.3361.75117.22165.4948.4730.66
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity239.0414.4732.3361.75117.22165.4948.4730.66
Total Liabilities & Stockholders Equity260.5317.1338.2373.19122.22171.6056.6135.10
Book Value Per Share-106.1010.9929.8160.18116.01163.77-69.93-33.26
Tangible Book Value Per Share-106.1010.9929.8160.18116.01163.77-69.93-33.26
Full-Time Employees751345402821-
Price to Book Ratio4.090.280.520.400.651.91-3.65-
Return on Assets-151.15-77.45-68.84-63.07-35.23-30.53-79.61-
Return on Equity-165.55-91.62-81.52-68.86-36.61-32.56-92.27-
Return on Invested Capital-87.28-134.90-118.37-99.26-43.98-20.98-74.99-51.76
Quick Ratio12.9814.076.315.7524.2330.427.077.87
Current Ratio12.9814.076.315.7524.2330.427.077.87

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-291.68-209.84-21.44-38.35-61.62-51.75-34.84-36.51-15.87
Depreciation0.350.030.180.830.490.440.190.110.00
Other Funds (Non Cash)199.93184.725.304.986.265.631.0414.883.11
Funds from Operations-91.40-25.09-15.96-32.54-54.87-45.68-33.61-21.52-12.76
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital32.2718.36-2.67-4.3711.94-6.62-4.592.19-0.93
Cash from Operating Activities-59.13-6.73-18.62-36.91-42.93-52.31-38.20-19.33-13.69
Capital Expenditures0.000.000.000.00-0.20-0.220.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00-0.330.00
Sale of Fixed Assets and Businesses0.000.000.000.080.000.000.000.000.00
Purchase or Sale of Investments-196.13-17.3711.6522.2512.58-47.830.000.000.00
Purchase of Investments-196.88-17.370.00-25.94-44.87-84.210.000.000.00
Sale Or Maturity of Investments0.750.0011.6548.1857.4536.380.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-196.13-17.3711.6522.3312.38-48.050.00-0.330.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock597.39266.840.002.880.510.00187.390.0034.36
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock597.39266.840.002.880.510.00187.390.0034.36
Proceedsfrom Stock Options596.65266.810.000.000.000.00187.390.0034.36
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.008.51
Change in Long Term Debt0.000.000.000.000.000.000.000.008.51
Issuance of Long Term Debt0.000.000.000.000.000.000.000.008.51
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities597.39266.840.002.880.510.00187.390.0042.87
Exchange Rate Effect-0.080.70-0.320.380.26-0.923.120.050.02
Net Change in Cash342.05243.45-7.29-11.32-29.78-101.27152.31-19.6129.21
Free Cash Flow-59.13-6.73-18.62-36.91-43.13-52.53-38.20-19.33-13.69
Preferred Dividends (Cash Flow)--0.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments528.48540.51532.90257.627.6110.21
Short Term Receivables0.840.880.890.900.990.99
Inventories0.000.000.000.000.000.00
Other Current Assets0.542.191.611.901.190.35
Total Current Assets529.86543.59535.41260.429.7911.55
Net Property, Plant & Equipment0.830.000.000.100.110.12
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets---0.00--
Other Assets1.940.050.030.000.842.02
Total Assets532.63543.64535.44260.5310.7413.69
Short Term Debt Incl. Current Port. of LT Debt0.150.000.000.010.010.01
Accounts Payable6.083.480.820.440.520.76
Other Current Liabilities29.6624.0722.9919.612.091.86
Total Current Liabilities35.8927.5523.8120.072.622.63
Long Term Debt0.950.001.341.391.401.40
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.030.030.030.030.050.05
Total Liabilities36.8727.5825.1821.494.074.08
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value130.00130.00131.11414.910.000.00
Common Equity365.76386.06379.15-175.876.679.61
Total Shareholders Equity495.76516.06510.26239.046.679.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity495.76516.06510.26239.046.679.61
Total Liabilities & Stockholders Equity532.63543.64535.44260.5310.7413.69
Book Value Per Share5.916.256.29-106.105.027.26
Tangible Book Value Per Share5.916.256.29-106.105.027.26
Full-Time Employees---7--
Price to Book Ratio4.094.14-0.244.580.510.37
Return on Assets-107.36-94.32-85.36-151.15-92.89-80.97
Return on Equity-116.11-100.00-89.97-165.55-114.81-99.96
Return on Invested Capital-6.44-6.04-5.43-83.49-38.85-31.21
Quick Ratio14.7619.7322.4812.983.734.39
Current Ratio14.7619.7322.4812.983.734.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-31.99-31.17-27.78-200.74-3.13-3.44
Depreciation0.260.010.070.010.010.01
Other Funds (Non Cash)6.506.143.13184.160.170.17
Funds from Operations-25.23-25.02-24.58-16.57-2.95-3.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital8.003.153.9817.140.331.02
Cash from Operating Activities-17.23-21.87-20.600.57-2.62-2.24
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-178.750.000.00-17.370.000.00
Purchase of Investments-179.500.000.00-17.370.000.00
Sale Or Maturity of Investments0.750.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-178.750.000.00-17.370.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.000.00
Change in Capital Stock5.1229.50295.92266.840.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.1229.50295.92266.840.000.00
Proceedsfrom Stock Options5.0729.28295.50266.810.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.1229.50295.92266.840.000.00
Exchange Rate Effect0.01-0.02-0.05-0.020.010.51
Net Change in Cash-190.867.62275.27250.02-2.60-1.73
Free Cash Flow-17.23-21.87-20.600.57-2.62-2.24

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.72%4.7M48.3M522.73K
2026-10-1510.71%5.2M48.1M520.86K
2026-09-309.84%4.7M48.1M540.71K
2026-09-159.83%4.7M48.1M594.08K
2026-08-318.58%4.1M48.1M564.65K
2026-08-1410.78%4.7M44.0M574.57K
2026-07-3110.64%4.9M46.0M585.38K
2026-07-1510.19%4.7M46.0M551.47K
2026-06-307.76%3.6M46.0M490.96K
2026-06-152.85%1.3M46.0M327.95K
2026-05-293.05%1.4M46.0M299.91K
2026-05-152.83%1.3M45.6M296.71K
2026-04-302.32%1.2M51.4M301.91K
2026-04-152.00%1.1M55.7M272.76K
2026-03-311.49%0.8M55.7M237.79K
2026-03-130.77%0.4M55.7M185.47K
2026-02-1318.72%0.3M1.5M168.79K
2026-01-3017.47%0.1M0.9M1.14M
2026-01-1516.13%0.2M1.1M1.14M
2025-12-3113.37%0.2M1.3M2.59M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-133Initial statement of beneficial ownership of securities2026-08-12SEC
2026-08-12EFFECTEffectiveness filing by commission orderSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10POSASRPost-effective amendment to an automatic shelf registration statement of Form S-3ASR or Form F-3ASRSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-108-A12B/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-28SCHEDULE 13GSEC
2026-07-208-KCurrent report2026-07-16SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-03SEC
2026-06-22144Filing for proposed sale of securities under Rule 144.SEC
2026-06-178-KCurrent report2026-04-28SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-083Initial statement of beneficial ownership of securities2026-05-01SEC
2026-05-048-KCurrent report2026-04-28SEC
2026-05-01ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09252.88K100
2026-080000
2026-07007.35K1
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010023.31K3
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.46%
Fairmount Funds Management LLC14.15%
Avoro Capital Advisors LLC6.14%
Venrock Adviser, LLC5.85%
BlackRock, Inc.5.14%
FCPM III SERVICES B.V.3.96%
RA CAPITAL MANAGEMENT, L.P.3.90%
VIKING GLOBAL INVESTORS LP3.75%
Jupiter Topco LLC3.71%
JPMORGAN CHASE & CO3.34%

Funds

Fund% owned
Fidelity Growth Company Fund2.97%
iShares Russell 2000 ETF2.20%
Fidelity Small Cap Growth Fund1.35%
JPMorgan Small Cap Growth Fund1.20%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.16%
Fidelity Small Cap Index Fund0.95%
Fidelity Growth Company K6 Fund0.87%
Select Health Care Portfolio0.81%
Fidelity Series Growth Company Fund0.74%
Select Biotechnology Portfolio0.74%

OakChart. DMRA. Cached 15 minutes.